CN104327166B - The dodecapeptide antigenic epitope of ochratoxin A and its application - Google Patents
The dodecapeptide antigenic epitope of ochratoxin A and its application Download PDFInfo
- Publication number
- CN104327166B CN104327166B CN201410549424.3A CN201410549424A CN104327166B CN 104327166 B CN104327166 B CN 104327166B CN 201410549424 A CN201410549424 A CN 201410549424A CN 104327166 B CN104327166 B CN 104327166B
- Authority
- CN
- China
- Prior art keywords
- ota
- antigenic epitope
- application
- ochratoxin
- antigenic epitopes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention belongs to biological technical field, is related to the dodecapeptide antigenic epitope of ochratoxin A, its amino acid sequence is FNLHQPIHNWPL.OTA antigenic epitopes of the present invention can replace expensive and strong toxicity OTA standard items, and it is applied to OTA immunology detection as competition antigen or solid-phase coating antigen, the antigenic epitope has an immune response characteristic similar to natural OTA molecules, and effect is very good.Reduce harm of the OTA to health, saved cost, there is very high application value.
Description
Technical field
The invention belongs to biological technical field, and in particular to ochratoxin A antigenic epitope and its application.
Background technology
Ochratoxin A (Ochratoxin A, OTA) is a kind of common mycotoxin, is aspergillus and Penicillium
Secondary metabolite caused by some strains.Research shows that OTA is easily accumulated in tissue, and its first target organs acted on is kidney
Dirty, liver, belongs to strong kidney and hepatotoxin, and experiment shows animal intake by after the feed of this endotoxin contamination, it may occur that
Acute or chronic nosotoxicosis.In addition, according to reported in literature, OTA also has carcinogenic, teratogenesis and mutagenicity.OTA toxigenic bacterium strain is wide
It is present in generally in nature, can be detected in the tissue of various crops, food, feed and the mankind and animal, blood
OTA pollution.The effective means that detection in time is prevention and controls it to endanger is carried out to OTA pollutions.
At present, the method for detecting OTA in food mainly has high performance liquid chromatography, gas-chromatography, thin-layer chromatography and immunology
The methods of detection, immunological detection method is with its high sensitivity, the advantage such as easy to detect, cost is cheap in OTA detection
To being widely applied.However, during immunological detection method is established, it is necessary to made using OTA standard items are raw material
Standby competition antigen or solid-phase coating antigen, OTA is not only expensive but also has extremely strong carcinogenicity, and testing staff is good for
Health and environment cause greatly to threaten, so as to constrain the application and popularization of immunological detection method to a certain extent.There is mirror
In this, people start to realize replacing for harmful small-molecule substance standard items using anti-idiotype and antigenic epitope technology
Generation, and make some progress.Phage display peptide library technology is mainly characterized by effectively filtering out and target target body
The phage-displayed polypeptides of specific bond, the technology are exploring the interphase interaction binding site of acceptor and part, are seeking high parent
The development of ligand molecular, exploration agnoprotein matter space structure epitope, new generation vaccine with power bioactivity etc. application is wide
It is general.
The present invention filters out energy and target molecule by using phage display peptide library technology from peptide storehouse（Anti- OTA monoclonals resist
Body）The polypeptide of specific binding（Antigenic epitope）, the antigenic epitope has similar to natural OTA molecules immune anti-
Characteristic is answered, by the OTA antigenic epitopes of acquisition, to replace expensive and strong toxicity OTA standard items, and as competition
Antigen or solid-phase coating antigen are applied to OTA immunology detection.
The content of the invention
The present invention, by target molecule solid-phase coating on ELISA Plate, puts into bacteriophage using anti-OTA monoclonal antibodies as target molecule
Random displaying dodecapeptide storehouse, carries out affine elutriation, obtains four kinds of OTA antigenic epitope.Their amino acid sequence is such as
Under：KLGFQLHQPSWP, FNLHQPIHNWPL, AQFFQLHSQAYS or DGFQLHTPFSAK.
The invention further relates to the nucleotide sequence for encoding above-mentioned antigenic epitope amino acid sequence, correspond to respectively：
AAGCTTGGGTTTCAGTTGCATCAGCCTAGTTGGCCG、
TTTAATTTGCATCAGCCGATTCATAATTGGCCGCTG、GCTCAGTTTTTTTAGCTGCATTCGCAGGCGTATTCG、
GATGGTTTTCAGTTGCATACTCCTTTTTCTGCTAAG
Above-mentioned antigenic epitope（Polypeptide）In structure, capitalization English letter represents a kind of 20 known natural L-forms respectively
One kind of amino acid residue or its D- type isomers, i.e. C represent cysteine residues, and D represents asparagicacid residue, and P represents dried meat
Histidine residue, R represent arginine residues, and K represents lysine residue, and H represents histidine residues, and I represents isoleucine residues, V
Valine residue is represented, Y represents tyrosine residue, and S represents serine residue, and F represents phenylalanine residue, and E represents glutamic acid
Residue, M represent methionine residues, and G represents glycine residue, and L represents leucine residue, and Q represents glutamine residue, W generations
Table trp residue, N represent asparagine residue, and A represents alanine residue, and T represents threonine residues.
The OTA antigenic epitopes that the present invention refers to（Polypeptide）Phage amplification, chemical synthesis or genetic engineering can be passed through
The mode of recombination expression is largely prepared.Phage amplification refers to displaying having OTA antigenic epitopes（Polypeptide）Phagocytosis
Body, by way of biology expands, amount reproduction production displaying has OTA antigenic epitopes（Polypeptide）Bacteriophage particles.Change
The amino acid sequence that synthesis refers to foundation OTA antigenic epitopes is learned, Peptide systhesis is carried out by way of chemically synthesized polypeptide.
The mode of genetic engineering recombination expression refers to that the gene of OTA antigenic epitopes will be encoded, by being cloned into expression vector, with more
The form of peptide-fusion protein carries out a large amount of preparations of OTA antigenic epitopes.
The invention further relates to application of the OTA antigenic epitopes in immunology detection analysis.Immunology detection
Type includes MBP enzyme linked immuno-adsorbent assay, colloidal gold immunochromatographimethod, immunodotting hybridization etc. and is based on Ag-Ab specific reaction
Immune analysis detection type.
OTA antigenic epitopes of the present invention（KLGFQLHQPSWP, FNLHQPIHNWPL, AQFFQLHSQAYS or
DGFQLHTPFSAK）In use, the mimic epitope of synthesis can be analyzed for immunology detection, Phage amplification will be passed through
The displaying of acquisition has OTA antigenic epitopes（Polypeptide）Bacteriophage particles be directly used in analysis detection, it is of course also possible to will
OTA antigenic epitopes are scaled off instead of OTA standard items from bacteriophage to carry out immunology detection analysis.
Further relate to application of the OTA antigenic epitopes with solid phase antigen or competition antigen in immunology detection analysis.
Further relate to application of the OTA antigenic epitopes as solid phase antigen in colloidal gold immunochromatographimethod detection and analysis.
Foregoing OTA antigenic epitopes can replace expensive and strong toxicity OTA standard items, and as competition antigen
Or solid-phase coating antigen is applied to OTA immunology detection, the antigenic epitope has similar to natural OTA molecules be immunized
Response characteristic, effect are very good.
The beneficial effects of the invention are as follows：OTA antigenic epitopes of the present invention can replace expensive and strong toxicity OTA
Standard items, and as competition antigen or solid-phase coating antigen be applied to OTA immunology detection, the antigenic epitope have with
The similar immune response characteristic of natural OTA molecules, effect are very good.Reduce harm of the OTA to health, saved into
This, has very high application value.
Brief description of the drawings
The indirect competitive ELISA standard curve that Fig. 1 is established with OTA antigenic epitopes.OTA antigenic epitopes Ph-1
（KLGFQLHQPSWP）、Ph-7（FNLHQPIHNWPL）、Ph-18（AQFFQLHSQAYS）, Ph-5 (DGFQLHTPFSAK) with it is anti-
The IC of OTA antibody50Value is respectively 553,495,509 pg/ml and 1.03 ng/ml.
Embodiment
The affine elutriation and its identification of the OTA antigenic epitopes of embodiment 1.
1）The affine elutriation of OTA antigenic epitopes：Specific method is：Anti- OTA is diluted with 10 mM PBS (pH 7.4)
Monoclonal antibody, and 96 hole elisa Plates, 4 DEG C of overnight incubations are coated with the μ g/mL of final concentration 100.Second day with TBST (50 mM
NaCl, pH 7.5 includes 0.1% Tween-20 (v/v)) washing 10 times after, add 300 μ l confining liquids（3% BSA-PBS）
4 DEG C are incubated 2 hours.Confining liquid is abandoned after 2 hours, is washed 5 times with TBST, 100 μ l phage peptide libraries are added per hole（Phage display technology
Show dodecapeptide storehouse, purchased from NEB companies, with 10 times of dilution bacteriophage stostes of TBS, about 1.0 × 1011pfu）, 22-26 DEG C of vibration is instead
Answer 1 hour.Uncombined bacteriophage is discarded, is washed 10 times with TBST, with reference to upper bacteriophage with 0.2 M Glycine-HCl
(pH 2.2) is eluted, and is neutralized immediately with the M Tris-HCl (pH 9.1) of 15 μ l 1.10 μ l wash-out bacteriophages are taken to survey drop
Degree, remaining, which is used to infecting 20 mL, grows to logarithm early stageE. coliER2738 bacterial strains are expanded.Use PEG/ within 3rd day
NaCl deposition and purification bacteriophages, and determine the titre of bacteriophage after amplification.
In the panning process of second, third wheel, coated anti-OTA MAb concentrations are respectively 75 μ g/mL and 50
μ g/mL, TBST concentration used are 0.25% and 0.5%, and remaining step is same as above.
2）The identification of positive phage clones：Random picking in the flat board of phage titre is determined after third round elutriation
20 bacteriophage spots, carry out the amplification of bacteriophage, using Immunofluorescent antibody detection method（Indirect Enzyme
Linked immunoasorbent assay, I-ELISA）The identification of positive phage clones is carried out, specific method is：It is first
First, anti-OTA monoclonal antibodies are diluted with 10 mM PBS (pH 7.4), 10 μ g/mL are coated with 96 hole elisa Plates, and 4 DEG C were incubated
Night.After second day is washed 3 times with PBST (10 mM PBS, 0.05% Tween-20 (v/v)), with containing 3% skimmed milk power
PBS closed, 37 DEG C be incubated 1 hour；Put into 100 μ l bacteriophages spots amplification liquid（1.0×1011pfu）, with original phagocytosis
As negative control, 37 DEG C are incubated 1 hour in body peptide storehouse；Add 1:The HRP of 5000 times of dilutions marks anti-M13 bacteriophages secondary antibody 100
μ l, 37 DEG C are incubated 1 hour；Add 100 μ l tmb substrate liquid, lucifuge colour developing 5min, ELIASA（Thermo Scientific
Multiskan FC）Read the absorption value at 450 nm.Choose OD450Phage clone of 2 times more than negative control is positive gram
It is grand.
3) identification of OTA antigenic epitopes：OTA antigenic epitopes are carried out using the method for indirect competitive ELISA
Identification, specific method are：Anti- OTA monoclonal antibodies are diluted with 10 mM PBS (pH 7.4), 10 μ g/mL coated elisa plates, 4
DEG C be incubated overnight；After second day is washed 3 times with PBST (10 mM PBS, 0.05% Tween-20 (v/v)), with containing 3%
The PBS of skimmed milk power is closed, and 37 DEG C are incubated 1 hour；Put into the bacteriophage gram that 50 μ l are accredited as the positive through indirect ELISA
It is grand（1.0×1011pfu）With 50 μ l OTA standard items（Concentration range is 0-20 ng/ml）, 37 DEG C are incubated 1 hour；Add 1:
The μ l of anti-M13 bacteriophages secondary antibody 100 of 5000 dilution HRP marks, 37 DEG C are incubated 1 hour；Add 100 μ l tmb substrate liquid, lucifuge
Develop the color 5min, reads OD450, anti-OTA monoclonal antibodies, and the bacteriophage that can be blocked by OTA standard items can be combined, is accredited as
OTA antigenic epitope.
The sequencing of the OTA antigenic epitope encoding genes of embodiment 2. and its determination of amino acid sequence
The bacteriophage for there are OTA antigenic epitopes by indirect competitive ELISA identification displaying is expanded, extracts phagocytosis
The DNA sequencing template of body.Simplified process is as follows：Phage amplification is carried out, after first step centrifugation, by 800 μ l containing on bacteriophage
It is transferred to a new centrifuge tube clearly.Add 200 μ l PEG/NaCl precipitating phages.Precipitation is resuspended in 100 μ l iodide after centrifugation
Buffer solution (10 mM Tris-HCl (pH 8.0), 1 mM EDTA, 4 M NaI), add 250 μ l absolute ethyl alcohols precipitation
DNA, precipitation is washed with 70% ethanol again after centrifugation（DNA sequencing template）.Precipitation is finally resuspended in 20 μ l aqua sterilisas, takes 2 μ l to enter
Row agarose gel electrophoresis are analyzed；5 μ L bacteriophages templates are taken to carry out DNA sequencing, its -96 gIII sequencing primer is：5’-HOCCC TCA TAG TTA GCG TAA CG-3’.OTA antigenic epitopes can be obtained according to DNA sequencing result and password sublist
Amino acid sequence.Their amino acid sequence is as follows：KLGFQLHQPSWP, FNLHQPIHNWPL, AQFFQLHSQAYS or
DGFQLHTPFSAK。
Application of the OTA antigenic epitopes of embodiment 3. as competition antigen in ELISA
(1) sample extraction
Weigh 5g samples（Cereal and its relevant food）, 25 milliliter of 60 % of addition methanol-PBS solution, 200 rpm
Vibration 5 minutes；After extract solution is filtered with No. 1 filter paper of whatman, 1 milliliter of filtrate is taken to add 4 milliliters of PBS（Phosphate
Buffer solution, pH=7.2）After mixing, as sample extracting solution is stand-by.
（2）Coating and closing
Anti- OTA monoclonal antibodies are diluted with 10 mM PBS (pH 7.4), 10 μ g/mL coated elisa plates, 4 DEG C were incubated
Night.After second day is washed 3 times with PBST (10 mM PBS, 0.05% Tween-20 (v/v)), with containing 3% skimmed milk power
PBS closed, it is stand-by with PBST board-washings 6 times after 37 DEG C are incubated 1 hour.
（3）The foundation of standard curve
Take out through step（2）The lath handled well, putting into 50 μ l displayings respectively per hole has biting for OTA antigenic epitopes
Thalline（1.0×1011pfu）With a series of 50 μ l OTA standard items of various concentrations, 37 DEG C are incubated 1 hour.Add 1:5000
The anti-M13 bacteriophages secondary antibody of HRP marks is diluted, 37 DEG C are incubated 1 hour.Then developed the color with tmb substrate, read OD450.It is dense with OTA
Degree logarithm is abscissa, Percentage bound（Add the OD in OTA hole450/ do not add OTA hole OD450×100%）For ordinate, build
Vertical indirect competition standard curve.As a result show that standard curve is S-type, linear dependence is preferable（Fig. 1）.Such as Fig. 1, with OTA antigens
The indirect competitive ELISA standard curve that mimic epitope is established.OTA antigenic epitopes Ph-1（KLGFQLHQPSWP）、Ph-7
（FNLHQPIHNWPL）、Ph-18（AQFFQLHSQAYS）, Ph-5 (DGFQLHTPFSAK) and anti-OTA antibody IC50 values difference
For 553,495,509 pg/ml and 1.03 ng/ml.
（4）The detection of sample
Take out through step（2）The lath handled well, putting into 50 μ l displayings respectively per hole has biting for OTA antigenic epitopes
Thalline（1.0×1011pfu）With testing sample extract solution, 37 DEG C are incubated 1 hour.Add 1:The anti-M13 of 5000 dilution HRP marks
Bacteriophage secondary antibody, 37 DEG C are incubated 1 hour.Then developed the color with tmb substrate, read OD450, calculations incorporated rate, and it is bent according to standard
Line, retrodict out the content of OTA in sample.
Application of the OTA antigenic epitopes of embodiment 4. as solid phase antigen in ELISA
(1) sample extraction
Weigh 5g samples（Cereal and its relevant food）, 25 milliliter of 60 % of addition methanol-PBS solution, 200 rpm
Vibration 5 minutes；After extract solution is filtered with No. 1 filter paper of whatman, 1 milliliter of filtrate is taken to add 4 milliliters of PBS（Phosphate
Buffer solution, pH=7.2）After mixing, as sample extracting solution is stand-by.
（2）Coating and closing
There is the bacteriophage of OTA antigenic epitopes with 10 mM PBS (pH 7.4) dilution displayings（2.0×1011pfu）,
100 microlitres are coated in ELISA Plate, 4 DEG C of overnight incubations.Second day with PBST (10 mM PBS, 0.05% Tween-20 (v/
V) after) washing 3 times, closed with the PBS containing 3% skimmed milk power, after 37 DEG C are incubated 1 hour, treated for 6 times with PBST board-washings
With.
（3）The foundation of standard curve
Take out through step（2）The lath handled well, the anti-OTA monoclonal antibodies of 50 μ l are put into respectively per hole（0.5 ng/
ml）With a series of 50 μ l OTA standard items of various concentrations, 37 DEG C are incubated 1 hour.Add 1:The sheep of 2000 dilution HRP marks
Anti- mouse IgG secondary antibodies, 37 DEG C are incubated 1 hour.Then developed the color with tmb substrate, read OD450.Using OTA log concentrations as abscissa, knot
Conjunction rate（Add the OD in OTA hole450/ do not add OTA hole OD450×100%）For ordinate, indirect competition standard song is established
Line.
（4）The detection of sample
Take out through step（2）The lath handled well, the anti-OTA monoclonal antibodies of 50 μ l are put into respectively per hole（0.5 ng/
ml）With a series of 50 μ l OTA standard items of various concentrations, 37 DEG C are incubated 1 hour.Add 1:The sheep of 2000 dilution HRP marks
Anti- mouse IgG secondary antibodies, 37 DEG C are incubated 1 hour.Then developed the color with tmb substrate, read OD450.Using OTA log concentrations as abscissa, knot
Conjunction rate（Add the OD in OTA hole450/ do not add OTA hole OD450×100%）For ordinate, indirect competition standard song is established
Line.
Application of the OTA antigenic epitopes of embodiment 5. as solid phase antigen in highly-pathogenic avian influenza
(1) sample extraction
Weigh 5g samples（Cereal and its relevant food）, 25 milliliter of 60 % of addition methanol-PBS solution, 200 rpm
Vibration 5 minutes；After extract solution is filtered with No. 1 filter paper of whatman, 1 milliliter of filtrate is taken to add 4 milliliters of PBS（Phosphate
Buffer solution, pH=7.2）After mixing, as sample extracting solution is stand-by.
（2）Bacteriophage and the dot matrix of control line
There is the bacteriophage of OTA antigenic epitopes with 10 mM PBS (pH 7.4) dilution displayings（2.0×1011pfu）,
Bacteriophage is lined on nitrocellulose filter with dot matrix instrument or micropipettor（Aperture 0.2-0.45 microns）, as detection
Line；The sheep anti-mouse igg secondary antibody that 0.5 mg/ml HRP is marked, same cellulose nitrate is lined with dot matrix instrument or micropipette
On plain film（Positioned at the top of detection line, distance is more than 5 millimeters）, as control line.
（3）Colloid gold label OTA antibody
Colloidal gold solution is added dropwise in OTA antibody（pH=8.2）In, stirred in drop, after 30 minutes, take 1% PEG to add
Enter in above-mentioned solution, 10% BSA solution of 1/10th volumes is added after continuing stirring 15 minutes, after stirring 15 minutes, stand
30 minutes, supernatant is removed after centrifugation, obtains the OTA antibody-solutions of colloid gold label.
（4）The assembling of colloidal-gold detecting-card
The OTA antibody point of colloid gold label is sprayed in glue gold pad（1.0 mcg/ml）, by sample pad, glue gold pad, point
The nitrocellulose filter and absorption paper of battle array detection line and control line are assembled, and are cut into test strips, are fitted into stand-by during detection blocks.
（5）The detection of sample
Sample extracting solution is added in sample pad, stands 10 minutes, if containing OTA and more than collaurum detection examination in sample
The detection threshold value of paper, then detection line region is not developed the color, and control line region is developed the color；If OTA is not contained in sample and is less than colloid
The detection threshold value of golden Test paper, then detection line region colour developing, control line region is also developed the color.If control line region is not developed the color, table
Bright test strips failure.
A large amount of preparations of the OTA antigenic epitopes of embodiment 5
（1）In a manner of Phage amplification
It will show that the bacteriophage for having OTA antigenic epitopes is added to 20 ml to be inoculated with ER 2738 culture, 37
Spend the h of 220 rpm shaken cultivations 4.5.Culture is transferred in another centrifuge tube, 4 DEG C of 10000 rpm centrifuges 10 min, will be upper
The clear % of top 80 is transferred in a fresh tube, adds the PEG/NaCl of 1/6 volume, 120 min are stood at 4 DEG C.4℃ 10000
Rpm centrifugations PEG/NaCL stands the min of solution 15.Supernatant is abandoned, residual supernatant is sucked after of short duration centrifugation.1mL TBS are added to enter
Row is resuspended, as Phage amplification liquid.
（2）Prepared in a manner of OTA antigenic epitopes-fusion protein
A.PCR expands the external source encoding gene of OTA antigenic epitopes
PCR reaction systems： (50 µL)
10 × Pyrobest Buffer (Mg2+ plus) 5µL
dNTP Mixture (each for 2.5 mM) 4µL
M13KE insert extension primer (10 mM） 1µL
-96 gIII sequencing primer (10 mM) 1µL
The μ L of phage DNA template 1
Pyrobest DNA Polymerase 0.5µL
Sterilize the μ L of ddH2O 37.5
PCR reaction conditions：95 DEG C of 5 min, then 95 DEG C of 30 sec, 55 DEG C of 30 sec, 72 DEG C of 40sec,
72 DEG C of 10 min totally 30 cycles
PCR products are purified using PCR products QIAquick Gel Extraction Kit, trace dna quantitative instrument quantifies.OTA antigens of the present invention
The coding gene sequence of mimic epitope corresponds to respectively：
AAGCTTGGGTTTCAGTTGCATCAGCCTAGTTGGCCG、TTTAATTTGCATCAGCCGATTCATAATTGGCC
GCTG、GCTCAGTTTTTTTAGCTGCATTCGCAGGCGTATTCG、GATGGTTTTCAGTTGCATACTCCTTTTTCTGCTAAG
B. the double digestion of external source encoding gene and expression vector
The external source code gene of ACC65I and Eag I enzymes and expression vector is respectively adopted（PMAl-pIII, NEB company,
MBP fusion proteins can be expressed）Carry out double digestion.
C. after digestion product connection and conversion
By plasmid pMal-PIII and purpose fragment with 1: 10（Mol ratio）Mix, 12 h connected in 16 DEG C of water-baths,
Take 10 μ L connection products to add in 100 μ L competent cells TB1, fully mix.After the min of ice bath 30,42 DEG C of water-bath heat shocks
90 s, add 600 μ L LB liquid mediums immediately after the min of ice bath 5,37 DEG C, and 200 rpm cultivate 1 h, 10000 rpm from
The min of the heart 2, suck supernatant and leave and take about 200 μ L, be coated on LB-A solids（Ampr）In culture medium, 37 DEG C are incubated overnight, and obtain
Positive colony.
The expression of OTA antigenic epitope-MBP fusion proteins
By the positive clone molecule of above-mentioned acquisition, a single bacterium colony is chosen from flat board and is inoculated in 5 mL LB-A, in 0.2% sucrose,
37 DEG C, 220 r/min, shaken cultivation is overnight, and overnight culture is pressed into 1 % inoculum concentrations（v/v）It is inoculated in 50 mL LB-A, 0.2
In % sucrose culture mediums, 3 bottles of inoculation respectively, 37 DEG C, 220 r/min shaken cultivations, when culture bacterial concentration OD600 reaches 0.6
When, IPTG to final concentration of 0.2 mmol/L, 220 r/min shaken cultivations, by inducer are added into three bottles of cultures（PEG
Solution）In 4 DEG C, 4000 g, 20 min of centrifugation collect bacterial sediment, abandon supernatant.Cell is resuspended in the mM Tris- of 400 mL 30
HCl, 20% sucrose, pH 8.0 (80 mL/g wet cell weights), EDTA to 1 mM is added, at room temperature concussion 5-10 min, 8000
G, 4 DEG C, 20 min being centrifuged, abandon supernatant, precipitation is resuspended in 5 mM MgSO4 of 400 ml precoolings, shakes 10 min on ice, and 8000
G, 4 DEG C, 20 min are centrifuged, retain supernatant, the M Tris-HCl, pH 7.4 of 8 mL 1 is added into supernatant, obtain OTA antigens
Mimic epitope-MBP fusion proteins.
SEQUENCE LISTING
<110>University Of Nanchang
<120>The dodecapeptide antigenic epitope of ochratoxin A and its application
<130> 1
<160> 8
<170> PatentIn version 3.3
<210> 1
<211> 12
<212> PRT
<213>Artificial sequence
<400> 1
Lys Leu Gly Phe Gln Leu His Gln Pro Ser Trp Pro
1 5 10
<210> 2
<211> 12
<212> PRT
<213>Artificial sequence
<400> 2
Phe Asn Leu His Gln Pro Ile His Asn Trp Pro Leu
1 5 10
<210> 3
<211> 12
<212> PRT
<213>Artificial sequence
<400> 3
Ala Gln Phe Phe Gln Leu His Ser Gln Ala Tyr Ser
1 5 10
<210> 4
<211> 12
<212> PRT
<213>Artificial sequence
<400> 4
Asp Gly Phe Gln Leu His Thr Pro Phe Ser Ala Lys
1 5 10
<210> 5
<211> 36
<212> DNA
<213>Artificial sequence
<400> 5
aagcttgggt ttcagttgca tcagcctagt tggccg 36
<210> 6
<211> 36
<212> DNA
<213>Artificial sequence
<400> 6
tttaatttgc atcagccgat tcataattgg ccgctg 36
<210> 7
<211> 36
<212> DNA
<213>Artificial sequence
<400> 7
gctcagtttt tttagctgca ttcgcaggcg tattcg 36
<210> 8
<211> 36
<212> DNA
<213>Artificial sequence
<400> 8
gatggttttc agttgcatac tcctttttct gctaag 36
Claims (6)
1. the antigenic epitope of ochratoxin A, it is characterised in that amino acid sequence is：FNLHQPIHNWPL.
2. encode the nucleotides of antigenic epitope described in claim 1.
3. nucleotides as claimed in claim 2, sequence correspond to：
TTTAATTTGCATCAGCCGATTCATAATTGGCCGCTG。
4. application of the antigenic epitope described in claim 1 in immunology detection analytical reagent is prepared.
5. application as claimed in claim 4, it is characterised in that ochratoxin A antigenic epitope is anti-with solid phase antigen or competition
Original shape formula prepares the application of immunology detection analytical reagent.
6. application as claimed in claim 4, it is characterised in that ochratoxin A antigenic epitope is prepared in the form of solid phase antigen
Colloidal gold immunochromatographimethod tests and analyzes the application of reagent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410549424.3A CN104327166B (en) | 2013-03-06 | 2013-03-06 | The dodecapeptide antigenic epitope of ochratoxin A and its application |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410549424.3A CN104327166B (en) | 2013-03-06 | 2013-03-06 | The dodecapeptide antigenic epitope of ochratoxin A and its application |
| CN201310071736.3A CN103145808B (en) | 2013-03-06 | 2013-03-06 | Antigen mimic epitope of ochratoxin A and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310071736.3A Division CN103145808B (en) | 2013-03-06 | 2013-03-06 | Antigen mimic epitope of ochratoxin A and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104327166A CN104327166A (en) | 2015-02-04 |
| CN104327166B true CN104327166B (en) | 2018-02-23 |
Family
ID=52401982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410549424.3A Expired - Fee Related CN104327166B (en) | 2013-03-06 | 2013-03-06 | The dodecapeptide antigenic epitope of ochratoxin A and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104327166B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105396559A (en) * | 2015-12-02 | 2016-03-16 | 南昌大学 | Affinity adsorption material based on anti-aflatoxin nanometer antibody |
| CN113173973B (en) * | 2021-05-24 | 2022-08-16 | 河南中泽生物工程有限公司 | Zearalenone mimic epitope and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101293916A (en) * | 2007-04-24 | 2008-10-29 | 上海国健生物技术研究院 | Monoclone antibody with combined function epiposition, specificity of osteopontin and uses thereof |
| CN101633932B (en) * | 2009-05-31 | 2013-05-01 | 江西科技师范学院 | Preparation method and application of high-density molecular simulation epitope peptide of ochratoxin A |
-
2013
- 2013-03-06 CN CN201410549424.3A patent/CN104327166B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN104327166A (en) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104530194B (en) | Antigenic epitope for ochratoxin A and its application | |
| CN103848895B (en) | The linear dodecapeptide antigenic epitope of aflatoxin B1 and its application | |
| CN104327166B (en) | The dodecapeptide antigenic epitope of ochratoxin A and its application | |
| CN104530195B (en) | Simulate antigenic epitope and its application of ochratoxin A | |
| CN103044527B (en) | Antigenic mimic epitope of gentamycin and application thereof | |
| CN108387740A (en) | A kind of epitope peptide, preparation method and the application of simulation Enrofloxacin | |
| CN103145808B (en) | Antigen mimic epitope of ochratoxin A and application thereof | |
| CN104311637B (en) | Simulation fumonisins B1Antigenic epitope and its application | |
| CN104356207B (en) | Fumonisins B1Dodecapeptide antigenic epitope and its application | |
| CN104311634B (en) | Aflatoxin B1Antigenic epitope AM 1 and its application | |
| CN103044526B (en) | Antigenic mimic epitope of vardenafil and application thereof | |
| CN103848896B (en) | The antigenic epitope Ph5 of bisphenol-A and application thereof | |
| CN104356208B (en) | It is a kind of to be directed to fumonisins B1Dodecapeptide antigenic epitope and its application | |
| CN104311635B (en) | For fumonisins B1Antigenic epitope and its application | |
| CN104311638B (en) | Fumonisins B can be simulated1Antigenic epitope and its application | |
| CN103848898B (en) | The antigenic epitope Ph3 of dihydroxyphenyl propane and application thereof | |
| CN103848897B (en) | The antigenic epitope Ph1 of dihydroxyphenyl propane and application thereof | |
| CN104788543B (en) | A kind of zearalenone antibody analog and its application based on polypeptide | |
| CN104311636B (en) | Antigen mimic epitope capable of mimicking fumonisins B1 and application of antigen mimic epitope | |
| CN104119425B (en) | The antigenic epitope of simulation norfloxacin and application thereof | |
| CN108358996A (en) | A kind of epitope peptide, preparation method and the application of simulation diethylstilbestrol | |
| CN108373495A (en) | A kind of epitope peptide, preparation method and the application of simulation dienestrol | |
| CN103342739B (en) | Antigenic mimic epitope of fumonisin B1 and application thereof | |
| CN103848899B (en) | The antigenic epitope Ph15 of bisphenol-A and application thereof | |
| CN103965290B (en) | The heptapeptide antigenic epitope of norfloxacin and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180223 |